ALKS 2680 Dose 2

Phase 3

AAlkermes, Inc.

ALKS 2680 Dose 2 is one of 3 therapeutic programs targeting Narcolepsy Type 1. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Narcolepsy Type 1Recruiting

Narcolepsy Type 2Recruiting

Narcolepsy Type 1Phase 3

Recruiting

Narcolepsy Type 2Phase 3

Recruiting

Competition

Competitive Landscape

4 competitors in Narcolepsy Type 1

#DrugCompanyPhaseTrials

ALKS 2680 Dose 2

AAlkermes, Inc.

Phase 3

2 2

ALKS 2680 Dose 1

AAlkermes, Inc.

Phase 3

2 3

TAK-360

Takeda

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Narcolepsy Type 2

NCT07502443

Phase 3Recruiting

Narcolepsy Type 1

NCT07455383

Q3 2027

Phase 3Recruiting

Narcolepsy Type 1

NCT07540897

Clinical

Trials by Indication[1]

Narcolepsy Type 12 trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 Study 304)

Recruiting·AAlkermes, Inc.·Phase 3·NCT07540897·150 enrolled

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 Study 302)

Recruiting·AAlkermes, Inc.·Phase 3·NCT07455383·150 enrolled

Narcolepsy Type 21 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 (Brilliance NT2 Study 303)

Recruiting·AAlkermes, Inc.·Phase 3·NCT07502443·176 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ALKS 2680 Dose 2. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for ALKS 2680 Dose 2. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Alkermes, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AAlkermes, Inc.

ALKS 2680 Dose 2

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Trials by Indication[1]

Narcolepsy Type 12 trials

Narcolepsy Type 21 trial

References

Drug Info

Quick Facts

Related News